 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
| «12345678910111213...1718» |
- | Blincyto (blinatumomab) / Astellas, Amgen
Trial completion date, Trial primary completion date: ECOG-ACRIN E1910: Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Mar 2, 2022
P3, N=488, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial completion date: Jun 2022 --> Sep 2025 | Trial primary completion date: Jun 2022 --> Sep 2025
- | Blincyto (blinatumomab) / Astellas, Amgen, Opdivo (nivolumab) / Ono Pharma, BMS
Trial suspension, Combination therapy, Checkpoint inhibition: AALL1821: A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL) (clinicaltrials.gov) - Mar 2, 2022
P2, N=550, Suspended, Sponsor: National Cancer Institute (NCI)
Trial completion date: Jun 2022 --> Sep 2025 | Trial primary completion date: Jun 2022 --> Sep 2025 Recruiting --> Suspended
- | Xpovio (selinexor) / Karyopharm, Menarini, FORUS Therap
Enrollment open, Enrollment change, Trial completion date, Trial primary completion date, Combination therapy: Selinexor With Combination With Induction/Consolidation Therapy in Acute Myeloid Leukemia Patients (clinicaltrials.gov) - Feb 22, 2022
P2, N=100, Recruiting, Sponsor: Wake Forest University Health Sciences
Recruiting --> Suspended Active, not recruiting --> Recruiting | N=28 --> 100 | Trial completion date: Jun 2022 --> Jun 2024 | Trial primary completion date: Jun 2022 --> Jun 2024
- | Elzonris (tagraxofusp) / Menarini, Nippon Shinyaku
Enrollment open: Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma (clinicaltrials.gov) - Feb 18, 2022
P1/2, N=40, Recruiting, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Recruiting | N=28 --> 100 | Trial completion date: Jun 2022 --> Jun 2024 | Trial primary completion date: Jun 2022 --> Jun 2024 Not yet recruiting --> Recruiting
- | Iclusig (ponatinib) / Takeda, Otsuka, Incyte
Trial completion date, Trial primary completion date: Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Feb 15, 2022
P2, N=100, Recruiting, Sponsor: M.D. Anderson Cancer Center
Not yet recruiting --> Recruiting Trial completion date: Oct 2021 --> Oct 2022 | Trial primary completion date: Oct 2021 --> Oct 2022
- | prexasertib (ACR-368) / Acrivon Therap
Trial completion date, Trial primary completion date, Combination therapy: Prexasertib (LY2606368), Cytarabine, and Fludarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome (clinicaltrials.gov) - Feb 15, 2022
P1, N=15, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Trial completion date: Oct 2021 --> Oct 2022 | Trial primary completion date: Oct 2021 --> Oct 2022 Trial completion date: May 2021 --> Dec 2022 | Trial primary completion date: May 2021 --> Dec 2022
- | navtemadlin (KRT-232) / Kartos Therap
Enrollment open, Enrollment change, Combination therapy: Testing the Addition of an Anti-cancer Drug, Navtemadlin, to the Usual Treatments (Cytarabine and Idarubicin) in Patients With Acute Myeloid Leukemia (clinicaltrials.gov) - Feb 15, 2022
P1b, N=24, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial completion date: May 2021 --> Dec 2022 | Trial primary completion date: May 2021 --> Dec 2022 Suspended --> Recruiting | N=57 --> 24
- | Neupogen (filgrastim) / Kyowa Kirin, Amgen
Trial completion date: Filgrastim, Cladribine, Cytarabine, and Mitoxantrone With Sorafenib in Treating Patients With Newly-Diagnosed, Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome (clinicaltrials.gov) - Feb 9, 2022
P1/2, N=84, Active, not recruiting, Sponsor: University of Washington
Suspended --> Recruiting | N=57 --> 24 Trial completion date: Jan 2023 --> Feb 2027
- | Zynlonta (loncastuximab tesirine) / Overland ADCT BioPharma, Mitsubishi Tanabe, SOBI
New P1 trial, Combination therapy: Loncastuximab Tesirine in Combination With Chemotherapy Prior to Stem Cell Transplant for the Treatment of Recurrent or Refractory Diffuse Large B-Cell Lymphoma (clinicaltrials.gov) - Feb 7, 2022
P1, N=20, Not yet recruiting, Sponsor: Fred Hutchinson Cancer Research Center
- | dexrazoxane / Generic mfg.
Trial completion date, Trial primary completion date, Adverse events: Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers (clinicaltrials.gov) - Feb 2, 2022
P2, N=100, Recruiting, Sponsor: M.D. Anderson Cancer Center
Trial completion date: Jan 2023 --> Feb 2027 Trial completion date: Dec 2020 --> Dec 2023 | Trial primary completion date: Dec 2020 --> Dec 2022
- | Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Trial completion, Preclinical, Enrollment change, Trial completion date, Trial primary completion date: Umbilical Cord Blood NK Cells, Rituximab, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Jan 21, 2022
P2, N=22, Completed, Sponsor: M.D. Anderson Cancer Center
Trial completion date: Dec 2020 --> Dec 2023 | Trial primary completion date: Dec 2020 --> Dec 2022 Active, not recruiting --> Completed | N=40 --> 22 | Trial completion date: Mar 2022 --> Aug 2021 | Trial primary completion date: Mar 2022 --> Aug 2021
- | Venclexta (venetoclax) / Roche, AbbVie
Trial completion date, Trial primary completion date: NCI-2018-01318: Venetoclax, Cladribine, Low Dose Cytarabine, and Azacitidine in Treating Patients With Previously Untreated Acute Myeloid Leukemia (clinicaltrials.gov) - Jan 21, 2022
P2, N=85, Recruiting, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed | N=40 --> 22 | Trial completion date: Mar 2022 --> Aug 2021 | Trial primary completion date: Mar 2022 --> Aug 2021 Trial completion date: Jan 2022 --> Jun 2023 | Trial primary completion date: Jan 2022 --> Jun 2023
- | cladribine / Generic mfg., mitoxantrone / Generic mfg., cytarabine / Generic mfg.
Enrollment change, Trial completion date, Trial termination, Trial primary completion date: Continuous Infusion Chemotherapy (CI-CLAM) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms (clinicaltrials.gov) - Jan 21, 2022
P1, N=13, Terminated, Sponsor: University of Washington
Trial completion date: Jan 2022 --> Jun 2023 | Trial primary completion date: Jan 2022 --> Jun 2023 N=45 --> 13 | Trial completion date: Dec 2024 --> Oct 2021 | Recruiting --> Terminated | Trial primary completion date: Dec 2024 --> Oct 2021; Terminated due to unfavorable risk-benefit ratio of investigational regimen.
- | Venclexta (venetoclax) / Roche, AbbVie, Walter and Eliza Hall Institute
Trial completion date, Trial primary completion date: NCI-2021-09185: Venetoclax and a Pediatric-Inspired Regimen for the Treatment of Newly Diagnosed B Cell Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Jan 11, 2022
P1, N=6, Not yet recruiting, Sponsor: City of Hope Medical Center
N=45 --> 13 | Trial completion date: Dec 2024 --> Oct 2021 | Recruiting --> Terminated | Trial primary completion date: Dec 2024 --> Oct 2021; Terminated due to unfavorable risk-benefit ratio of investigational regimen. Trial completion date: Oct 2023 --> May 2023 | Trial primary completion date: Oct 2023 --> May 2023
- | peposertib (M3814) / EMD Serono
Trial completion date, Trial primary completion date, Combination therapy: Testing the Addition of an Anti-cancer Drug, M3814, to the Usual Treatment (Mitoxantrone, Etoposide, and Cytarabine) for Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Jan 6, 2022
P1, N=48, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial completion date: Oct 2023 --> May 2023 | Trial primary completion date: Oct 2023 --> May 2023 Trial completion date: Dec 2021 --> Dec 2022 | Trial primary completion date: Dec 2021 --> Dec 2022
- | Bylantra (devimistat) / Cornerstone Pharma, Ono Pharma
Trial completion date: CPI-613, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Granulocytic Sarcoma (clinicaltrials.gov) - Jan 5, 2022
P2, N=50, Active, not recruiting, Sponsor: Wake Forest University Health Sciences
Trial completion date: Dec 2021 --> Dec 2022 | Trial primary completion date: Dec 2021 --> Dec 2022 Trial completion date: Feb 2022 --> Jul 2022
- | peposertib (M3814) / EMD Serono
Enrollment open, Combination therapy: Testing the Addition of an Anti-cancer Drug, M3814, to the Usual Treatment (Mitoxantrone, Etoposide, and Cytarabine) for Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Dec 22, 2021
P1, N=48, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial completion date: Feb 2022 --> Jul 2022 Suspended --> Recruiting
- | Xpovio (selinexor) / Karyopharm, Menarini, FORUS Therap
Trial completion date, Trial primary completion date, Combination therapy: Selinexor With Combination With Induction/Consolidation Therapy in Acute Myeloid Leukemia Patients (clinicaltrials.gov) - Dec 22, 2021
P2, N=28, Active, not recruiting, Sponsor: Wake Forest University Health Sciences
Suspended --> Recruiting Trial completion date: Dec 2021 --> Jun 2022 | Trial primary completion date: Dec 2021 --> Jun 2022
- | Venclexta (venetoclax) / Roche, AbbVie, Walter and Eliza Hall Institute
New P1 trial: NCI-2021-09185: Venetoclax and a Pediatric-Inspired Regimen for the Treatment of Newly Diagnosed B Cell Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Dec 14, 2021
P1, N=6, Not yet recruiting, Sponsor: City of Hope Medical Center
- | nelarabine / Generic mfg.
Trial completion date, Trial primary completion date: Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma (clinicaltrials.gov) - Dec 9, 2021
P2, N=160, Recruiting, Sponsor: M.D. Anderson Cancer Center
Trial completion date: Dec 2021 --> Jun 2022 | Trial primary completion date: Dec 2021 --> Jun 2022 Trial completion date: Oct 2021 --> Oct 2022 | Trial primary completion date: Oct 2021 --> Oct 2022
- | Ninlaro (ixazomib) / Takeda, Rituxan (rituximab) / Roche
Trial completion date: Combination Chemotherapy, Rituximab, and Ixazomib Citrate in Treating Patients With Non-Hodgkin Lymphoma (clinicaltrials.gov) - Dec 8, 2021
P1/2, N=38, Active, not recruiting, Sponsor: Northwestern University
Trial completion date: Oct 2021 --> Oct 2022 | Trial primary completion date: Oct 2021 --> Oct 2022 Trial completion date: Jul 2022 --> Jul 2024
- | uproleselan sodium (APL-106) / GlycoMimetics
New P1 trial, Combination therapy: NCI-2021-10020: Highest Dose of Uproleselan in Combination With Fludarabine and Cytarabine for Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Mixed Phenotype Acute Leukemia Relapsed or Refractory and That Expresses E-selectin Ligand on the Cell Membrane (clinicaltrials.gov) - Dec 6, 2021
P1, N=51, Not yet recruiting, Sponsor: Children's Oncology Group
- sEphB4-HSA / VasGene, National Cancer Institute, Marqibo (vincristine liposomal) / Servier, Aurobindo
Enrollment change, Trial termination, Combination therapy: EphB4-HSA Fusion Protein and Cytarabine /or Liposomal Vincristine in Patients With Recurrent or Refractory Acute Leukemia (clinicaltrials.gov) - Nov 30, 2021
P1, N=3, Terminated, Sponsor: University of Southern California
Trial completion date: Jul 2022 --> Jul 2024 N=44 --> 3 | Recruiting --> Terminated; Study drug supply issue
- || Venclexta (venetoclax) / Roche, AbbVie, Walter and Eliza Hall Institute
Enrollment open: Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms (clinicaltrials.gov) - Nov 29, 2021
P1, N=20, Recruiting, Sponsor: University of Washington
N=44 --> 3 | Recruiting --> Terminated; Study drug supply issue Not yet recruiting --> Recruiting
- | uproleselan sodium (APL-106) / GlycoMimetics
Trial suspension: Daunorubicin and Cytarabine With or Without Uproleselan in Treating Older Adult Patients With Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy (clinicaltrials.gov) - Nov 23, 2021
P2/3, N=670, Suspended, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Recruiting --> Suspended
- || Neupogen (filgrastim) / Kyowa Kirin, Amgen
Enrollment closed, Trial completion date, Trial primary completion date: Filgrastim, Cladribine, Cytarabine, and Mitoxantrone With Sorafenib in Treating Patients With Newly-Diagnosed, Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome (clinicaltrials.gov) - Nov 12, 2021
P1/2, N=84, Active, not recruiting, Sponsor: University of Washington
Recruiting --> Suspended Recruiting --> Active, not recruiting | Trial completion date: Oct 2025 --> Jan 2023 | Trial primary completion date: Oct 2022 --> Jan 2022
- | cladribine / Generic mfg., mitoxantrone / Generic mfg., cytarabine / Generic mfg.
Trial completion, Trial completion date, HEOR: Higher or Lower Dose Cladribine, Cytarabine, and Mitoxantrone in Treating Medically Less Fit Patients With Newly Diagnosed Acute Myeloid Leukemia or Myeloid Neoplasm (clinicaltrials.gov) - Nov 8, 2021
P2, N=50, Completed, Sponsor: University of Washington
Recruiting --> Active, not recruiting | Trial completion date: Oct 2025 --> Jan 2023 | Trial primary completion date: Oct 2022 --> Jan 2022 Active, not recruiting --> Completed | Trial completion date: Dec 2025 --> Feb 2021
- | Venclexta (venetoclax) / Roche, AbbVie, Walter and Eliza Hall Institute, milademetan (RAIN-32) / Rain Oncology
Trial completion date, Trial primary completion date, Combination therapy: Milademetan Tosylate and Low-Dose Cytarabine With or Without Venetoclax in Treating Participants With Recurrent or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Nov 2, 2021
P1/2, N=58, Recruiting, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed | Trial completion date: Dec 2025 --> Feb 2021 Trial completion date: May 2022 --> Dec 2023 | Trial primary completion date: May 2021 --> Dec 2022
- | thioguanine / Generic mfg.
Trial completion date: AALL15P1: Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement (clinicaltrials.gov) - Oct 26, 2021
P2, N=78, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial completion date: May 2022 --> Dec 2023 | Trial primary completion date: May 2021 --> Dec 2022 Trial completion date: Sep 2022 --> Dec 2024
- | pevonedistat (MLN4924) / Takeda
Trial completion date, Trial primary completion date, Combination therapy: Pevonedistat, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia (clinicaltrials.gov) - Oct 18, 2021
P1b, N=53, Recruiting, Sponsor: University of Southern California
Trial completion date: Sep 2022 --> Dec 2024 Trial completion date: Apr 2021 --> Apr 2023 | Trial primary completion date: Apr 2020 --> Apr 2022
- | Venclexta (venetoclax) / Roche, AbbVie, Inqovi (decitabine/cedazuridine) / Otsuka
Enrollment open, Combination therapy, Tumor mutational burden: NCI-2021-02246: Testing Oral Decitabine and Cedazuridine (ASTX727) in Combination With Venetoclax for Higher-Risk Acute Myeloid Leukemia Patients (clinicaltrials.gov) - Oct 17, 2021
P1/2, N=18, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial completion date: Apr 2021 --> Apr 2023 | Trial primary completion date: Apr 2020 --> Apr 2022 Not yet recruiting --> Recruiting
- | peposertib (M3814) / EMD Serono
Trial suspension, Combination therapy: Testing the Addition of an Anti-cancer Drug, M3814, to the Usual Treatment (Mitoxantrone, Etoposide, and Cytarabine) for Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Oct 15, 2021
P1, N=48, Suspended, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Recruiting --> Suspended
- | pevonedistat (MLN4924) / Takeda
Enrollment change, Trial completion date, Trial primary completion date, Combination therapy: ADVL1712: Pevonedistat, Azacitidine, Fludarabine Phosphate, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome (clinicaltrials.gov) - Oct 7, 2021
P1, N=12, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Suspended N=38 --> 12 | Trial completion date: Dec 2021 --> Oct 2022 | Trial primary completion date: Dec 2021 --> Sep 2021
- | Venclexta (venetoclax) / Roche, AbbVie
Trial completion date, Trial primary completion date: OSU-17225: Venetoclax, Carmustine, Etoposide, Cytarabine, and Melphalan Before Stem Cell Transplant in Treating Participants With Relapsed or Refractory Non-Hodgkin Lymphoma (clinicaltrials.gov) - Oct 6, 2021
P1/2, N=19, Active, not recruiting, Sponsor: Ohio State University Comprehensive Cancer Center
N=38 --> 12 | Trial completion date: Dec 2021 --> Oct 2022 | Trial primary completion date: Dec 2021 --> Sep 2021 Trial completion date: Dec 2021 --> Dec 2022 | Trial primary completion date: Dec 2021 --> Dec 2022
- | Qinprezo (vosaroxin) / Denovo
Trial completion date, Combination therapy, Tumor mutational burden: VITAL: Vosaroxin and Infusional Cytarabine in Treating Patients With Untreated Acute Myeloid Leukemia (clinicaltrials.gov) - Sep 28, 2021
P2, N=42, Active, not recruiting, Sponsor: Vanderbilt-Ingram Cancer Center
Trial completion date: Dec 2021 --> Dec 2022 | Trial primary completion date: Dec 2021 --> Dec 2022 Trial completion date: Jul 2021 --> Jul 2022
- | pinometostat (EPZ-5676) / Ipsen
Enrollment closed, Combination therapy: Pinometostat With Standard Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and MLL Gene Rearrangement (clinicaltrials.gov) - Sep 8, 2021
P1b/2, N=37, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial completion date: Jul 2021 --> Jul 2022 Recruiting --> Active, not recruiting
- | Blincyto (blinatumomab) / Astellas, Amgen
Trial completion date, Trial primary completion date, Combination therapy: AALL1731: A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia (clinicaltrials.gov) - Sep 5, 2021
P3, N=6720, Recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Trial completion date: Jun 2027 --> Dec 2027 | Trial primary completion date: Jun 2027 --> Dec 2027
- | Besponsa (inotuzumab ozogamicin) / Pfizer, UCB
Trial completion date, Trial primary completion date: AALL1732: Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy (clinicaltrials.gov) - Sep 5, 2021
P3, N=3698, Recruiting, Sponsor: Children's Oncology Group
Trial completion date: Jun 2027 --> Dec 2027 | Trial primary completion date: Jun 2027 --> Dec 2027 Trial completion date: May 2027 --> Jun 2029 | Trial primary completion date: May 2027 --> Jun 2029
- | Elzonris (tagraxofusp) / Menarini, Nippon Shinyaku
New P1/2 trial: Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma (clinicaltrials.gov) - Sep 1, 2021
P1/2, N=40, Not yet recruiting, Sponsor: M.D. Anderson Cancer Center
- | Xpovio (selinexor) / Karyopharm, Menarini, FORUS Therap
Trial completion date, Trial primary completion date, Combination therapy: Selinexor With Combination With Induction/Consolidation Therapy in Acute Myeloid Leukemia Patients (clinicaltrials.gov) - Sep 1, 2021
P2, N=28, Active, not recruiting, Sponsor: Wake Forest University Health Sciences
Trial completion date: May 2027 --> Jun 2029 | Trial primary completion date: May 2027 --> Jun 2029 Trial completion date: Aug 2021 --> Dec 2021 | Trial primary completion date: Aug 2021 --> Dec 2021
- | Asparec (PEGylated recombinant Erwinia chrysantemi-derived L-asparaginase) / Jazz
Enrollment open: Fludarabine, Cytarabine, and Pegcrisantaspase for the Treament of Relapsed or Refractory Leukemia (clinicaltrials.gov) - Aug 31, 2021
P1, N=62, Recruiting, Sponsor: M.D. Anderson Cancer Center
Trial completion date: Aug 2021 --> Dec 2021 | Trial primary completion date: Aug 2021 --> Dec 2021 Not yet recruiting --> Recruiting
- | Starasid (cytarabine ocfosfate) / Nippon Kayaku
Trial primary completion date: FLT PET/CT in Measuring Response in Patients With Previously Untreated Acute Myeloid Leukemia (clinicaltrials.gov) - Aug 18, 2021
P2, N=57, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Trial primary completion date: Jul 2021 --> Jul 2022
- ||| Rydapt (midostaurin) / Novartis, Mylotarg (gemtuzumab ozogamicin) / UCB, PDL, Pfizer
Trial suspension, Combination therapy: NCI-2019-01726: Gentuzumab Ozogamicin and Midostaurin Combination With Standard Cytarabine and Danunorubi Midostaurin as a Novel Approach to Treating Patients With Newly Diagnosed FLT-3 Mutated Acute Myeloid Leukemia (clinicaltrials.gov) - Aug 18, 2021
P1, N=24, Suspended, Sponsor: OHSU Knight Cancer Institute
Trial primary completion date: Jul 2021 --> Jul 2022 Recruiting --> Suspended
- | Venclexta (venetoclax) / Roche, AbbVie, Inqovi (decitabine/cedazuridine) / Otsuka
Trial completion date, Trial primary completion date, Combination therapy, Tumor mutational burden: NCI-2021-02246: Testing Oral Decitabine and Cedazuridine (ASTX727) in Combination With Venetoclax for Higher-Risk Acute Myeloid Leukemia Patients (clinicaltrials.gov) - Aug 18, 2021
P1/2, N=18, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Suspended Trial completion date: Dec 2022 --> Aug 2023 | Trial primary completion date: Dec 2022 --> Aug 2023
- | Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Enrollment closed, Preclinical, Trial completion date, Trial primary completion date: Umbilical Cord Blood NK Cells, Rituximab, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Aug 16, 2021
P2, N=40, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Trial completion date: Dec 2022 --> Aug 2023 | Trial primary completion date: Dec 2022 --> Aug 2023 Recruiting --> Active, not recruiting | Trial completion date: Mar 2021 --> Mar 2022 | Trial primary completion date: Mar 2021 --> Mar 2022
- | Xalkori (crizotinib) / Pfizer, Adcetris (brentuximab vedotin) / Takeda, Pfizer
Enrollment closed, Combination therapy: Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma (clinicaltrials.gov) - Aug 4, 2021
P2, N=137, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting | Trial completion date: Mar 2021 --> Mar 2022 | Trial primary completion date: Mar 2021 --> Mar 2022 Suspended --> Active, not recruiting
- | Blincyto (blinatumomab) / Astellas, Amgen
Trial primary completion date: AALL1331: Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Jul 2, 2021
P3, N=670, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Suspended --> Active, not recruiting Trial primary completion date: Dec 2022 --> Jun 2021
- | Blincyto (blinatumomab) / Astellas, Amgen
Trial primary completion date: ECOG-ACRIN E1910: Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Jul 2, 2021
P3, N=488, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Dec 2022 --> Jun 2021 Trial primary completion date: Jun 2021 --> Jun 2022
- | Blincyto (blinatumomab) / Astellas, Amgen, Opdivo (nivolumab) / Ono Pharma, BMS
Trial completion date, Trial primary completion date, Combination therapy, Checkpoint inhibition: AALL1821: A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL) (clinicaltrials.gov) - Jun 30, 2021
P2, N=550, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Jun 2021 --> Jun 2022 Trial completion date: Dec 2023 --> Jun 2028 | Trial primary completion date: Dec 2023 --> Jun 2028
- | Arzerra (ofatumumab) / Novartis, Genmab
Trial completion date, Combination therapy: NCI-2011-03562: Ofatumumab in Combination With Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine Sulfate, and Dexamethasone Alternating With Ofatumumab in Combination With Cytarabine and Methotrexate in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma (clinicaltrials.gov) - Jun 29, 2021
P2, N=37, Active, not recruiting, Sponsor: Roswell Park Cancer Institute
Trial completion date: Dec 2023 --> Jun 2028 | Trial primary completion date: Dec 2023 --> Jun 2028 Trial completion date: Oct 2021 --> Feb 2022